SPYRE THERAPEUTICS, INC. Proceeds from (Payments for) Other Financing Activities
SPYRE THERAPEUTICS, INC. (SYRE) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SPYRE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2024 was $1.00K.
- SPYRE THERAPEUTICS, INC. proceeds from (payments for) other financing activities for fiscal 2023 was -$16.00K.
| Period end | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $1.00K 10-K · filed 2026-02-19 |
| 2023-12-31 | -$16.00K 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |